PBE's Holdings Could Mean 18% Gain Potential
September 09, 2021 at 08:12 AM EDT
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Dynamic Biotechnology & Genome ETF (PBE), we found that the implied analyst target price for the ETF based upon its underlying holdings is $91.95 per unit.